stoxline Quote Chart Rank Option Currency Glossary
  
Bio-Rad Laboratories, Inc. (BIO)
283.21  6.05 (2.18%)    02-18 16:00
Open: 275.5
High: 284.99
Volume: 495,988
  
Pre. Close: 277.16
Low: 275.5
Market Cap: 8,110(M)
Technical analysis
2025-02-18 4:42:18 PM
Short term     
Mid term     
Targets 6-month :  391.84 1-year :  436.46
Resists First :  335.48 Second :  373.69
Pivot price 333.41
Supports First :  273.67 Second :  227.69
MAs MA(5) :  298.76 MA(20) :  339.08
MA(100) :  339 MA(250) :  321.5
MACD MACD :  -13.1 Signal :  -4.7
%K %D K(14,3) :  6.9 D(3) :  6.5
RSI RSI(14): 25.8
52-week High :  387.98 Low :  262.11
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BIO ] has closed above bottom band by 4.4%. Bollinger Bands are 166% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 285.65 - 287.55 287.55 - 289.26
Low: 270.85 - 273.25 273.25 - 275.42
Close: 279.47 - 283.28 283.28 - 286.73
Company Description

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Headline News

Tue, 18 Feb 2025
Bio-Rad Laboratories (NYSE:BIO) Downgraded by StockNews.com to "Hold" - MarketBeat

Tue, 18 Feb 2025
BIO Stock Might Rise Following the Offer to Acquire Stilla - Yahoo Finance

Tue, 18 Feb 2025
Is There An Opportunity With Bio-Rad Laboratories, Inc.'s (NYSE:BIO) 39% Undervaluation? - Simply Wall St

Mon, 17 Feb 2025
Bio-Rad Laboratories (NYSE:BIO.B) Issues Quarterly Earnings Results - MarketBeat

Mon, 17 Feb 2025
Bio-Rad Laboratories (NYSE:BIO) Sees Large Volume Increase After Strong Earnings - MarketBeat

Sat, 15 Feb 2025
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2024 Earnings Call Transcript - Insider Monkey

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 23 (M)
Shares Float 19 (M)
Held by Insiders 15.6 (%)
Held by Institutions 84.5 (%)
Shares Short 584 (K)
Shares Short P.Month 656 (K)
Stock Financials
EPS -65.35
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 234.63
Profit Margin -71.9 %
Operating Margin 13 %
Return on Assets (ttm) 1.7 %
Return on Equity (ttm) -24.1 %
Qtrly Rev. Growth -2 %
Gross Profit (p.s.) 60.64
Sales Per Share 112.12
EBITDA (p.s.) 20.13
Qtrly Earnings Growth 0 %
Operating Cash Flow 455 (M)
Levered Free Cash Flow 375 (M)
Stock Valuations
PE Ratio -4.34
PEG Ratio 0
Price to Book value 1.2
Price to Sales 2.52
Price to Cash Flow 14.26
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android